Literature DB >> 18335239

Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan.

Shinichi Kobayashi1, Shizuko Murayama, Sayaka Takanashi, Kumiko Takahashi, Sachiko Miyatsuka, Tomoko Fujita, Sadato Ichinohe, Yuichi Koike, Toshitaka Kohagizawa, Hirosumi Mori, Yasushi Deguchi, Kaoru Higuchi, Hiroaki Wakasugi, Tatsuya Sato, Yasuyuki Wada, Masato Nagata, Nobuhiko Okabe, Osamu Tatsuzawa.   

Abstract

In this paper, we examined the details of severe infections, treatment efficacies, and the prognoses of 23 Japanese patients with chronic granulomatous disease (CGD). We described the mean ages at diagnosis and follow-up, which were 2.8 years (range, 0.7-10 years) and 14.9 years (range, 0.2-28.4 years), respectively. There were three deaths, two from Aspergillus pneumonia and one from liver abscess. Eighteen of the 23 patients (78%) had a complete loss of gp91phox, and three had p22-phox and one had p67phox deficiencies. Aspergillus species were found in 45% of 174 severe infections. The mean height and weight of the 20 surviving patients were -0.8 +/- 1.3SD and -1.9 +/- 1.9SD below the means for age, respectively. Short stature and underweight (below the 10th percentile of the means) for age were seen in 22% and 17% of the patients, respectively. This growth retardation reflects the severity of the disease. At 20 years of age, there was 87% survival. Ongoing prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) or antifungal drugs was given in 16 and 11 patients, respectively. Interferon-gamma (IFN-gamma) was given once a week to 14 patients. Four patients underwent hematopoietic stem cell transplantation (HSCT) and are currently well. There were infections observed in three of 21 identified related carriers of X-linked CGD. A carrier with a liver abscess had 5% normal neutrophils during the acute phase of infection, which returned to 40% normal neutrophils after recovery. The high survival rate in this hospital results from regular follow-up and prophylaxis with TMP-SMX and anti-fungal drugs beginning at the time of diagnosis, along with treatment with weekly IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335239     DOI: 10.1007/s00431-008-0680-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  19 in total

1.  A fatal granulomatous disease of childhood; the clinical, pathological, and laboratory features of a new syndrome.

Authors:  R A BRIDGES; H BERENDES; R A GOOD
Journal:  AMA J Dis Child       Date:  1959-04

2.  A fatal granulomatosus of childhood: the clinical study of a new syndrome.

Authors:  H BERENDES; R A BRIDGES; R A GOOD
Journal:  Minn Med       Date:  1957-05

3.  Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization.

Authors:  A Rösen-Wolff; W Soldan; K Heyne; J Bickhardt; M Gahr; J Roesler
Journal:  Ann Hematol       Date:  2001-02       Impact factor: 3.673

4.  Chronic granulomatous disease. Report on a national registry of 368 patients.

Authors:  J A Winkelstein; M C Marino; R B Johnston; J Boyle; J Curnutte; J I Gallin; H L Malech; S M Holland; H Ochs; P Quie; R H Buckley; C B Foster; S J Chanock; H Dickler
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

Review 5.  Genetic, biochemical, and clinical features of chronic granulomatous disease.

Authors:  B H Segal; T L Leto; J I Gallin; H L Malech; S M Holland
Journal:  Medicine (Baltimore)       Date:  2000-05       Impact factor: 1.889

6.  Long-term follow-up and outcome of 39 patients with chronic granulomatous disease.

Authors:  J Liese; S Kloos; V Jendrossek; T Petropoulou; U Wintergerst; G Notheis; M Gahr; B H Belohradsky
Journal:  J Pediatr       Date:  2000-11       Impact factor: 4.406

7.  Successful low toxicity hematopoietic stem cell transplantation for high-risk adult chronic granulomatous disease patients.

Authors:  Tayfun Güngör; Jörg Halter; Anne Klink; Sonja Junge; Katrin D M Stumpe; Reinhard Seger; Urs Schanz
Journal:  Transplantation       Date:  2005-06-15       Impact factor: 4.939

8.  Bone marrow transplantation in chronic granulomatous disease.

Authors:  N Kamani; C S August; S D Douglas; E Burkey; A Etzioni; H W Lischner
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

9.  Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease.

Authors:  R Mouy; F Veber; S Blanche; J Donadieu; R Brauner; J C Levron; C Griscelli; A Fischer
Journal:  J Pediatr       Date:  1994-12       Impact factor: 4.406

10.  Urinary tract disorders in patients with chronic granulomatous disease.

Authors:  H Aliabadi; R Gonzalez; P G Quie
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

View more
  27 in total

1.  Monocyte/macrophage-specific NADPH oxidase contributes to antimicrobial host defense in X-CGD.

Authors:  Yuka Okura; Masafumi Yamada; Futoshi Kuribayashi; Ichiro Kobayashi; Tadashi Ariga
Journal:  J Clin Immunol       Date:  2015-02-10       Impact factor: 8.317

Review 2.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

Review 3.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

4.  Advances in treatment for chronic granulomatous disease.

Authors:  Elizabeth M Kang; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

5.  Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.

Authors:  Jennifer R Yonkof; Ashish Gupta; Pingfu Fu; Elizabeth Garabedian; Jignesh Dalal
Journal:  J Clin Immunol       Date:  2019-05-20       Impact factor: 8.317

6.  Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease.

Authors:  Toshinao Kawai; Nobuyuki Watanabe; Midori Yokoyama; Yumiko Nakazawa; Fumihiro Goto; Toru Uchiyama; Masataka Higuchi; Takanobu Maekawa; Eiichiro Tamura; Satoshi Nagasaka; Masayuki Hojo; Masafumi Onodera
Journal:  J Clin Immunol       Date:  2014-09-04       Impact factor: 8.317

Review 7.  Recent advances in transplantation for primary immune deficiency diseases: a comprehensive review.

Authors:  M Teresa de la Morena; Robert P Nelson
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

8.  Infection Profile in Chronic Granulomatous Disease: a 23-Year Experience from a Tertiary Care Center in North India.

Authors:  Amit Rawat; Pandiarajan Vignesh; Avinash Sharma; Jitendra K Shandilya; Madhubala Sharma; Deepti Suri; Anju Gupta; Vikas Gautam; Pallab Ray; Shivaprakash M Rudramurthy; Arunaloke Chakrabarti; Kohsuke Imai; Shigeaki Nonoyama; Osamu Ohara; Yu L Lau; Surjit Singh
Journal:  J Clin Immunol       Date:  2017-03-22       Impact factor: 8.317

9.  BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes.

Authors:  P V Soeiro-Pereira; A Falcai; C A Kubo; E B Oliveira-Júnior; O C Marques; E Antunes; A Condino-Neto
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 10.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Hematol Oncol Clin North Am       Date:  2012-11-22       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.